A Robust and Sensitive Instrument for Quantification of N-Nitroso Argatroban impurity at 0.3 ppm in Argatroban Drug Product

Significance of the topic

Trace levels of nitrosamine impurities in drug products pose significant safety and regulatory challenges. N-Nitroso Argatroban, an impurity related to the active pharmaceutical ingredient (API), may form during manufacturing or storage due to trace nitrites in excipients. Sensitive, robust analytical methods are essential to ensure patient safety, meet stringent regulatory limits, and maintain product quality.

Objectives and Study Overview

• Develop a reliable method for quantifying N-Nitroso Argatroban at a limit of quantification (LOQ) of 0.3 ppm in Argatroban drug product.
• Overcome matrix effects and achieve acceptable spiked recovery in complex formulation matrices.
• Demonstrate method sensitivity, linearity, and robustness using advanced LC-MS/MS techniques.

Methodology and Instrumentation

• Sample preparation: extraction approach with minimal concentration to reduce matrix interferences and improve recovery (target range 70–120 %).
• Chromatography: Waters Acquity UPLC H-Class Plus system equipped with HSS T3 column for efficient separation of impurity and API peaks.
• Mass spectrometry: Waters Xevo TQ-S Cronos tandem quadrupole MS operated in RADAR mode to capture both multiple reaction monitoring (MRM) and full scan spectra simultaneously.
• Data acquisition: RADAR scan enabled clear differentiation of NDSRI peak elution after the API, allowing diversion of the API peak to waste and preventing source contamination.

Main Results and Discussion

• Sensitivity: signal-to-noise ratio >1000 at 0.05 ppm for N-Nitroso Argatroban, demonstrating exceptional detection capability.
• Linearity: calibration range from 0.05 to 50 ppm with high correlation across the span.
• LOQ and LOD: method LOQ established at 0.3 ppm, instrument limit of detection below 0.005 ppm.
• Recovery: average spiked recovery of 94 % confirmed method accuracy within targeted acceptance limits.
• Robustness: RADAR mode facilitated rapid method optimization and troubleshooting of matrix effects, ensuring reliable performance in routine analysis.

Benefits and Practical Applications

• Enables precise monitoring of N-Nitroso Argatroban impurities to comply with regulatory guidelines and safeguard patient health.
• Provides a streamlined analytical workflow using minimal sample preparation and fast UPLC separations.
• Reduces instrument contamination by diverting major API peaks, lowering maintenance requirements and downtime.
• Offers a transferable method for quality control and stability testing in pharmaceutical laboratories.

Future Trends and Applications

• Expansion of RADAR acquisition modes for simultaneous qualitative and quantitative analysis of diverse impurities.
• Integration of real-time data analytics and AI-driven method optimization to further reduce development timelines.
• Application to a broader range of nitrosamine-related impurities in other drug products and biologics.
• Advances in high-resolution MS and novel column chemistries to enhance sensitivity and selectivity.

Conclusion

This study demonstrates a robust, highly sensitive LC-MS/MS approach for quantifying N-Nitroso Argatroban at trace levels in Argatroban drug products. The combination of advanced sample preparation, UPLC separation, and Xevo TQ-S Cronos RADAR acquisition ensures accurate, reliable results suitable for regulatory compliance and routine quality control.